From Yahoo Finance: 2025-04-26 12:10:00

RBC Capital notes that Biohaven has withdrawn its application for troriluzole in spinocerebellar ataxia. Investor sentiment is bearish, with many believing U.S. approval is crucial for stock recovery. While EMA’s strict rare disease regulations could limit readthroughs, the firm still sees upside potential with a $61 price target, maintaining an Outperform rating.



Read more at Yahoo Finance: Biohaven share price undervaluing pipeline potential, says RBC Capital